Acadia Pharmaceuticals calls Parkinson's disease treatment trial 'encouraging'

By Jennifer Chiou

New York, June 22 - Acadia Pharmaceuticals Inc. said results from a trend analysis of its multi-center Phase II clinical trial of ACP-103 for treatment-induced psychosis in patients with Parkinson's disease were "encouraging."

ACP-103, a small molecule drug candidate discovered and currently under development by Acadia, is a new therapy for patients with Parkinson's disease, a chronic neurological disorder that results from the degeneration of neurons in a region of the brain that controls movement.

The ongoing double-blind, placebo-controlled, dose-escalation Phase II clinical trial evaluates the efficacy and tolerability of ACP-103 in 60 patients who suffer from treatment-induced dysfunction.

The results of the interim trend analysis were based on data from the first 30 patients to complete the study, of which 13 patients were treated with ACP-103 and 17 patients were administered a placebo.

Results of the interim analysis demonstrated that, relative to the placebo group, the ACP-103 treatment group showed a greater reduction in psychotic symptoms on rating scales assessing the severity of the illness as well as positive symptoms.

Positive changes included reductions in hallucinations and delusions.

"These interim results are encouraging and increase our confidence that ACP-103 may prove to be an effective therapy for the debilitating drug-induced psychosis suffered by many Parkinson's disease patients," said Uli Hacksell, chief executive officer of Acadia, in a news release.

"We remain on track to complete patient enrollment and report results from the complete Phase II trial in late 2005 or early 2006."

The San Diego, Calif.-based biopharmaceutical company focuses on treatments for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.